
Small Pool Heat-Treated Intermediate Purity Factor VIII Concentrate
Small pool heat-treated intermediate purity concentrate may be the most suitable and cost-effective solution for some countries attempting sufficiency and
Year: 2016
Language: Polish
Author(s): World Federation of Hemophilia
Format: Document
Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese
This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for any errors or changes to content from the original English edition. Patient organizations interested in translating a WFH resource must first obtain permission from the WFH, available here.
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

Small pool heat-treated intermediate purity concentrate may be the most suitable and cost-effective solution for some countries attempting sufficiency and

This monograph provides guidelines for the production of single-donor cryoprecipitate.

This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Russian Treatment for bleeding

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese 包括的血友病医療を受けている患者は、血友病治療センター以外の医療機関で治療を受けた患者よりも死亡率が低く、出血の合併症による入院率が低くなっています。

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese このファクトシートには、血友病患者に基本的な治療およびケアを提供するメリットが記載されています。適切なケアには、血友病治療センターおよび治療用製剤の利用、医療関係者、患者、家族に対する教育が含まれます。

Also Available In: English, Spanish, French, Arabic, Russian, Simplified Chinese 安全で規制を順守している血漿由来凝固因子濃縮製剤で血友病患者を治療することは、出血性疾患患者への社会経済的影響、さらには政府やコミュニティ、家族から求められる長期的支援を直接軽減します。